Huntington’s Disease Therapy Uses the Power of Repression

A team led by researchers at Sangamo Therapeutics has shown the first, direct, demonstration of allele-selective transcriptional repression at the huntingtin locus. This opens up a novel therapeutic approach to targeting the gene responsible for Huntington's disease.

Ultivue Closes $22M Series C Financing, with Plans to Expand UltiMapper,...

Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, has completed a $22 million Series C financing.

Immunotherapy Targets Emerging Infectious Diseases

Ebola, Zika, and other terrifying diseases are the stuff of “hot zones,” but they inspire cool technologies such as mRNA vaccines, neutralizing antibodies, and designer DNA immunotherapies.

Advanced Mass Spectrometry Drives Translational Cancer Biomarker Research beyond Discovery

Labs participating in the Cancer Moonshot are using the latest mass spec techniques to streamline proteomic workflows and advance biomarker development.

Setting New Standards for CRO/CDMO Industry

LakePharma is defying tradition and has evolved into the first US-based, full-scale CRDMO to provide an integrated suite of end-to-end services for the biologics development community.

Splendid Isolation for Cells Screened via High-Throughput Microfluidics

A scientist in biologics discovery or cell line development, working at peak efficiency, typically can screen between 5000 and 10,000 antibody-secreting cells per day. What if we could increase daily output to 40 million? Imagine what could happen.

Obesity Takes the Brakes Off Neurological Mechanism that Stops Overeating

Researchers used a combination of single-cell RNA sequencing and two-photon calcium imaging to identify obesity-related changes to glutamatergic neurons in the lateral hypothalamic area of the brain, which in mice fed a a normal diet, functionally put the brakes on overeating. In animals fed a high-fat diet, the neurons were modified in a way that disrupted the natural feeding suppression system to promote overeating and obesity.

Anticancer Drug Candidate Inhibits Novel Alzheimer’s Disease Target to Protect Neurons

Studies in cultured neurons and mouse models suggest have found that using an anticancer drug candidate to inhibit an enzyme that acts downstream of existing challenging Alzheimer’s disease targets can help to protect neurons from amyloid beta-induced dendritic spine degeneration.

BMS Selling Celgene’s Otezla to Address FTC “Concerns” on $74B Deal

Bristol-Myers Squibb (BMS) said today it will divest itself of the psoriasis drug Otezla® (apremilast) as part of its planned $74 billion acquisition of Celgene, in order to address what it called “concerns” raised by the U.S. Federal Trade Commission concerns about the blockbuster deal.

HDAC Inhibitor Found to Sensitize Cancers to Anti-PD1 Therapy

Using mouse models of B-cell lymphoma, researchers added a histone deacetylase inhibitor that sensitized cancers to anti-PD1 therapy.

Recently Featured

Stay Connected

Scroll Up